Subcutaneous formulation of RoActemra launched

Patients with moderate to severe active rheumatoid arthritis (RA) can now self-administer RoActemra (tocilizumab), following the launch of a prefilled syringe for subcutaneous injection.

After proper training, patients with rheumatoid arthritis (pictured) may self-inject RoActemra if deemed appropriate | SCIENCE PHOTO LIBRARY
After proper training, patients with rheumatoid arthritis (pictured) may self-inject RoActemra if deemed appropriate | SCIENCE PHOTO LIBRARY

Tocilizumab is the only interleukin-6 receptor antagonist available for both subcutaneous and intravenous administration in RA. The 162mg prefilled syringe for subcutaneous administration can be used both as monotherapy and in combination with methotrexate or other DMARDs.

"The versatility that RoActemra now offers is extremely valuable to the patient, not to mention the freeing up of precious consulting time for clinicians," said Professor Choy, Professor of Rheumatology at the Cardiff Institute of Infection & Immunity.

The SUMMACTA study showed that the efficacy of subcutaneous tocilizumab was comparable to that of the intravenous formulation. The adverse event profiles of the subcutaneous and intravenous formulations were also comparable, with the exception of a higher incidence of injection site reactions observed with the subcutaneous injection.

View RoActemra drug record

Further information: Roche 

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more